Exact Sciences Corp. ’s Cologuard stool test gained unanimous support as a colorectal cancer screening tool from an FDA panel March 27, setting it up for a likely approval and, potentially, a Medicare national coverage determination in the near term.
FDA’s Molecular and Clinical Genetics Advisory Panel said the test was safe, effective, and has benefits that exceed its risks...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?